186RNL

DRUG3 trials

Sponsors

Plus Therapeutics, Cerenome, NYU Langone Health

Conditions

Leptomeningeal MetastasesLeptomeningeal Metastasis

Phase 1

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Active, not recruitingNCT05034497

Plus TherapeuticsLeptomeningeal Metastasis

Start: 2021-12-06End: 2026-06-30Target: 18Updated: 2025-03-26

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

RecruitingNCT07098806

CerenomeLeptomeningeal Metastasis

Start: 2025-07-02End: 2031-10-02Target: 24Updated: 2026-09-09

Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases

Not yet recruitingNCT07674693

NYU Langone HealthLeptomeningeal Metastases

Start: 2026-07-01End: 2031-07-01Target: 29Updated: 2026-06-29

Related Papers

CTNI-67. PHASE 1 MULTICENTER STUDY OF MULTIPLE DOSES OF RHENIUM (186RE) OBISBEMEDA (REYOBIQ) FOR LEPTOMENINGEAL METASTASES: RATIONALE, DESIGN, AND PRELIMINARY COHORT 1 DATA

Neuro-Oncology2025-11-01

LMAP-21 PRELIMINARY CLINICAL DATA IN THE PHASE 1/2A DOSE ESCALATION TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN LEPTOMENINGEAL METASTASES (LM): THE RESPECT-LM TRIAL

Neuro-Oncology Advances2023-08-014 citations